Clinical Trials Directory

Trials / Recruiting

RecruitingNCT06559345

A Prospective, Open-label, Randomized Controlled, Multicenter Clinical Study of Haplo-HSCT Using a TBI or TMLI Conditioning Regimen for Pediatric ALL

A Prospective, Open-label, Randomized Controlled, Multicenter Clinical Study of Haploidentical Hematopoietic Stem Cell Transplantation Using a TBI or TMLI Conditioning Regimen for Pediatric Acute Lymphoblastic Leukemia

Status
Recruiting
Phase
Phase 2
Study type
Interventional
Enrollment
276 (estimated)
Sponsor
The First Affiliated Hospital of Zhengzhou University · Academic / Other
Sex
All
Age
1 Year – 17 Years
Healthy volunteers
Not accepted

Summary

This study aims to compare the effects of two different conditioning regimens on patients with acute lymphoblastic leukemia (ALL) undergoing haploidentical allogeneic hematopoietic stem cell transplantation (haplo-HSCT): Total Body Irradiation (TBI) and Total Marrow, Central Nervous System and Lymphoid Irradiation (TMLI). Both regimens are supported and recommended by literature; however, there is no definitive evidence favoring one over the other. We hypothesize that the TMLI regimen, compared to the TBI regimen, may more effectively eliminate leukemia cells in the bone marrow and lymphoid tissues, thereby reducing the risk of relapse, while also minimizing damage to normal tissues, thus reducing conditioning-related toxicity and transplant-related mortality. This study aims to provide evidence for the optimal conditioning regimen for haplo-HSCT in pediatric ALL patients, with the goal of improving patient quality of life and survival outcomes.

Conditions

Interventions

TypeNameDescription
RADIATIONTMLIThe total dose of TMLI is 12 Gy, administered on days -7, -6, and -5, with 2 Gy per fraction, twice daily, for a total of 6 fractions.
RADIATIONTBIThe total dose of TBI is 12 Gy, administered on days -7, -6, and -5, with 2 Gy per fraction, twice daily, for a total of 6 fractions.
DRUGCyclophosphamideThe total dose of cyclophosphamide is 120 mg/kg, administered over 2 days on days -4 and -3.

Timeline

Start date
2025-03-17
Primary completion
2029-07-31
Completion
2029-08-31
First posted
2024-08-19
Last updated
2025-02-18

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT06559345. Inclusion in this directory is not an endorsement.